Kazuyoshi Kawakami*, Takashi Yokokawa*, Kazuo Kobayashi*, Takahito Sugisaki*, Kenichi Suzuki*, Mitsukuni Suenaga†, Kensei Yamaguchi†, Ayaka Inoue‡, Yoshiaki Machida‡, Toshiharu Yamaguchi†, Toshihiro Hama*
Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071
Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine
plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study
were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease
adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011,
and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study
assessed adherence… More >
Login
Register
